SAN DIEGO, June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Novartis has announced plans to acquire Avidity Biosciences for $12 billion in cash, marking one of the largest pharmaceutical deals of the year. The Swiss healthcare company is betting big on a new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results